0000950103-17-010087.txt : 20171019 0000950103-17-010087.hdr.sgml : 20171019 20171019152230 ACCESSION NUMBER: 0000950103-17-010087 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20171019 DATE AS OF CHANGE: 20171019 EFFECTIVENESS DATE: 20171019 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Entera Bio Ltd. CENTRAL INDEX KEY: 0001638097 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-297095 FILM NUMBER: 171144572 BUSINESS ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 BUSINESS PHONE: 972-2-532-7151 MAIL ADDRESS: STREET 1: KIRYAT HADASSAH, MINRAV BUILDING STREET 2: FIFTH FLOOR CITY: JERUSALEM STATE: L3 ZIP: 9112002 D 1 primary_doc.xml X0708 D LIVE 0001638097 Entera Bio Ltd. JERUSALEM BIO PARK FIFTH FLOOR JERUSALEM L3 ISRAEL 9112002 972-54-535-2683 ISRAEL None None Corporation true Phillip Schwartz Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Executive Officer Director Gerald Lieberman Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director Luke M. Beshar Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director Zeev Bronfeld Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director Yonatan Malca Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director Roger Garceau Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director Chaim Davis Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director David Ben Ami Jerusalem Bio Park 5th floor Jerusalem L3 ISRAEL 9112002 Director Pharmaceuticals Decline to Disclose 06b false 2017-10-04 false true false 9996 GP NURMENKARI INC. 153480 None None 122 EAST 42ND STREET SUITE 1616 NEW YORK NY NEW YORK 10168 CA CALIFORNIA FL FLORIDA IL ILLINOIS MD MARYLAND MA MASSACHUSETTS NH NEW HAMPSHIRE NJ NEW JERSEY NY NEW YORK OH OHIO TX TEXAS false 7000000 2022944 4977056 false 30 202294 0 Sales commission relates to cash fee of 10% from $2,022,944.28 gross proceeds. Amounts do not include additional compensation in the form of warrants for the purchase of up to 10% of the number of equity securities sold. 0 false Entera Bio Ltd. /s/ Phillip Schwartz Phillip Schwartz Chief Executive Officer 2017-10-18